Our findings of older DNAm age and/or increased age accel in both ER/PR–positive and HER2/neu–negative subgroups than in the relevant counterparts and in those without BC development are in line with those of previous tissue-based studies [6, 8, 31, 50, 62]. This evidence concerns the gene ERBB2 and breast cancer.